These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 28325253)
1. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Yoodee J; Permsuwan U; Nimworapan M Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228 [TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Wang XF; Feng Y; Chen Y; Gao BL; Han BH Sci Rep; 2014 Apr; 4():4813. PubMed ID: 24770591 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437 [TBL] [Abstract][Full Text] [Related]
5. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness? Chiu L; Chow R; DeAngelis C; Lock M; Simone CB Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973 [TBL] [Abstract][Full Text] [Related]
6. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Hocking CM; Kichenadasse G Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741 [TBL] [Abstract][Full Text] [Related]
7. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study. Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269 [TBL] [Abstract][Full Text] [Related]
8. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Yang T; Liu Q; Lu M; Ma L; Zhou Y; Cui Y Br J Clin Pharmacol; 2017 Jul; 83(7):1369-1379. PubMed ID: 28112422 [TBL] [Abstract][Full Text] [Related]
10. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis. Natale JJ Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis. Alhifany AA; McBride A; Almutairi AR; Cheema E; Shahbar A; Alatawi Y; Alharbi AS; Babiker H; MacDonald K; Aapro M; Abraham I Support Care Cancer; 2020 Mar; 28(3):1031-1039. PubMed ID: 31823054 [TBL] [Abstract][Full Text] [Related]
12. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. Bosnjak SM; Dimitrijevic J; Djordjevic F Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. Filetti M; Lombardi P; Giusti R; Falcone R; Scotte F; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G Cancer Treat Rev; 2023 Apr; 115():102512. PubMed ID: 36774658 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Meena JP; Gupta AK; Jat KR; Anandani G; Sasidharan A; Tanwar P J Pediatr Hematol Oncol; 2023 Oct; 45(7):361-369. PubMed ID: 37539996 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365 [TBL] [Abstract][Full Text] [Related]
17. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. Zhou JG; Huang L; Jin SH; Xu C; Frey B; Ma H; Gaipl US ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079622 [TBL] [Abstract][Full Text] [Related]
18. QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Liu J; Tan L; Zhang H; Li H; Liu X; Yan Z; Chen J; Yang H; Zhang D Eur J Cancer Care (Engl); 2015 May; 24(3):436-43. PubMed ID: 25404537 [TBL] [Abstract][Full Text] [Related]
19. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131 [TBL] [Abstract][Full Text] [Related]
20. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy. Slimano F; Netzer F; Borget I; Lemare F; Besse B Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]